ZNTL NASDAQ
Zentalis Pharmaceuticals, Inc.
1W: -17.1%
1M: -23.9%
3M: -57.6%
YTD: +44.5%
1Y: +15.8%
3Y: -89.0%
5Y: -97.4%
$1.98
-0.09 (-4.35%)
Pre-Market: $2.09 (+0.11, +5.81%)
Weekly Expected Move ±11.3%
$2
$2
$2
$2
$3
Credit Risk of going bust: higher than 80% of companies Debt: 21.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the third-riskiest tenth, about 1 in 140 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 99%), Zentalis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $37.7M against a stock market value of $140.9M.
Distance to default 2.58 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.1M (short-term plus half of long-term), stock volatility 117.5%; Altman Z'' -18.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.03 (down 99%), Zentalis Pharmaceuticals, Inc. would be worth roughly what it owes.
Total debt $37.7M against a stock market value of $140.9M.
Distance to default 2.58 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $4.1M (short-term plus half of long-term), stock volatility 117.5%; Altman Z'' -18.17. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$15.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$140.9M
52W Range1.21-6.95
Volume1,721,943
Avg Volume1,263,868
Beta1.94
Dividend—
Analyst Ratings
Company Info
CEOJulia Marie Eastland
Employees106
SectorHealthcare
IndustryBiotechnology
IPO Date2020-04-03
Websitezentalis.com
10275 Science Center Drive
San Diego, CA 92121
US
San Diego, CA 92121
US
212 433 3791
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA.
Latest News
Zentalis rises as lead asset extends survival in mid-stage trial for ovarian cancer
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Receives Consensus Recommendation of “Hold” from Analysts
BlackRock Inc. Invests $18.20 Million in Zentalis Pharmaceuticals, Inc. $ZNTL
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Bruns Ingmar | A-Award | 9,727 | $2.18 | 2026-09-30 |
| WALTERS GROUP | P-Purchase | 4,335,000 | $3.50 | 2026-08-14 |
| Johnson David Michae | A-Award | 57,100 | — | 2026-06-16 |
| Skvarka Jan | A-Award | 57,100 | — | 2026-06-16 |
| Walker Luke Nathanie | A-Award | 57,100 | — | 2026-06-16 |